These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34739739)

  • 1. The potential role of lysergic acid diethylamide for psychological assisted therapy: A meta-analysis of randomised controlled trials in healthy volunteers.
    Li H; Zhong Y; Yang S; Wang J; Li X; Xu J; Gao H; Chen G
    Hum Psychopharmacol; 2022 May; 37(3):e2825. PubMed ID: 34739739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety pharmacology of acute LSD administration in healthy subjects.
    Holze F; Caluori TV; Vizeli P; Liechti ME
    Psychopharmacology (Berl); 2022 Jun; 239(6):1893-1905. PubMed ID: 34515824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study.
    Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Holze F; Liechti ME; Feilding A; Ramaekers JG; Kuypers KPC
    Eur Neuropsychopharmacol; 2020 Dec; 41():81-91. PubMed ID: 33082016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.
    Schmid Y; Enzler F; Gasser P; Grouzmann E; Preller KH; Vollenweider FX; Brenneisen R; Müller F; Borgwardt S; Liechti ME
    Biol Psychiatry; 2015 Oct; 78(8):544-53. PubMed ID: 25575620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants.
    Holze F; Liechti ME; Hutten NRPW; Mason NL; Dolder PC; Theunissen EL; Duthaler U; Feilding A; Ramaekers JG; Kuypers KPC
    Clin Pharmacol Ther; 2021 Mar; 109(3):658-666. PubMed ID: 32975835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.
    Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME
    Clin Pharmacokinet; 2017 Oct; 56(10):1219-1230. PubMed ID: 28197931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Ley L; Müller F; Becker AM; Straumann I; Vizeli P; Kuehne SS; Roder MA; Duthaler U; Kolaczynska KE; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2022 May; 47(6):1180-1187. PubMed ID: 35217796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers.
    Bershad AK; Schepers ST; Bremmer MP; Lee R; de Wit H
    Biol Psychiatry; 2019 Nov; 86(10):792-800. PubMed ID: 31331617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers.
    Ramaekers JG; Hutten N; Mason NL; Dolder P; Theunissen EL; Holze F; Liechti ME; Feilding A; Kuypers KP
    J Psychopharmacol; 2021 Apr; 35(4):398-405. PubMed ID: 32842825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.
    Holze F; Vizeli P; Ley L; Müller F; Dolder P; Stocker M; Duthaler U; Varghese N; Eckert A; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2021 Feb; 46(3):537-544. PubMed ID: 33059356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.
    Krebs TS; Johansen PØ
    J Psychopharmacol; 2012 Jul; 26(7):994-1002. PubMed ID: 22406913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.
    Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects.
    Strajhar P; Schmid Y; Liakoni E; Dolder PC; Rentsch KM; Kratschmar DV; Odermatt A; Liechti ME
    J Neuroendocrinol; 2016 Mar; 28(3):12374. PubMed ID: 26849997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial.
    Murphy RJ; Sumner R; Evans W; Ponton R; Ram S; Godfrey K; Forsyth A; Cavadino A; Krishnamurthy Naga V; Smith T; Hoeh NR; Menkes DB; Muthukumaraswamy S
    Biol Psychiatry; 2023 Sep; 94(6):511-521. PubMed ID: 36997080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
    Family N; Maillet EL; Williams LTJ; Krediet E; Carhart-Harris RL; Williams TM; Nichols CD; Goble DJ; Raz S
    Psychopharmacology (Berl); 2020 Mar; 237(3):841-853. PubMed ID: 31853557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
    Schmid Y; Gasser P; Oehen P; Liechti ME
    J Psychopharmacol; 2021 Apr; 35(4):362-374. PubMed ID: 33853422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants.
    Straumann I; Ley L; Holze F; Becker AM; Klaiber A; Wey K; Duthaler U; Varghese N; Eckert A; Liechti ME
    Neuropsychopharmacology; 2023 Dec; 48(13):1840-1848. PubMed ID: 37258715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study.
    Family N; Hendricks PS; Williams LT; Luke D; Krediet E; Maillet EL; Raz S
    J Psychopharmacol; 2022 Mar; 36(3):321-336. PubMed ID: 35253516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
    Pouyan N; Younesi Sisi F; Kargar A; Scheidegger M; McIntyre RS; Morrow JD
    CNS Drugs; 2023 Dec; 37(12):1027-1063. PubMed ID: 37999867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality.
    Dolder PC; Schmid Y; Müller F; Borgwardt S; Liechti ME
    Neuropsychopharmacology; 2016 Oct; 41(11):2638-46. PubMed ID: 27249781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.